CDK4/6抑制剂用作早期乳腺癌辅助治疗?获益不确定,危害却必然
文章重新评估MonarchE(阿贝西利2年)与NATALEE(瑞波西利3年)两项辅助治疗研究,认为其无侵袭性疾病生存获益因对照组早期脱落、非随机删失而显得脆弱;不良事件明显更高,NATALEE中COVID-19相关死亡令人严重关切;辅助CDK4/6抑制剂费用空前,NATALEE策略可能影响全球发病率最高的乳腺癌中高达35%的新诊断患者;在无安慰剂对照确证数据或更佳获益人群识别前,作者反对在ER+/HER2-早期乳腺癌中常规辅助使用。
要点
- 两项辅助研究对照组早期出现过多脱落或失访,开放标签下脱落可能非随机。
- 基于重建Kaplan-Meier曲线,作者认为结果仍脆弱,易受信息性删失影响。
- 两项研究不良事件明显更高,NATALEE中COVID-19相关死亡令人严重关切。
核心结论
- 在缺乏安慰剂对照确证数据或更佳获益人群识别前,作者反对在ER+/HER2-早期乳腺癌中常规辅助使用CDK4/6抑制剂。
研究设计与样本
- 本文为对MonarchE(阿贝西利2年辅助治疗)与NATALEE(瑞波西利3年辅助治疗)两项辅助治疗研究的重新评估。
主要发现
- 两项研究对照组早期出现过多脱落或失访;因研究为开放标签,脱落可能基于社会经济因素与替代选择而非随机。
- 基于重建的Kaplan-Meier曲线,作者认为结果仍脆弱,易受信息性删失影响。
- 两项研究不良事件均明显更高,NATALEE中COVID-19相关死亡令人严重关切。
- 辅助CDK4/6抑制剂费用空前;NATALEE策略可能影响高达35%的新诊断乳腺癌患者。
临床怎么用
- 作者反对在ER+/HER2-早期乳腺癌中常规辅助使用CDK4/6抑制剂,理由为获益不确定且危害必然。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CDK4/6 inhibitors are oral agents inhibiting key molecules of the cell cycle regulation. In patients with endocrine receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer, the combination of CDK4/6 inhibitors with endocrine therapy is an effective treatment in the metastatic setting. Now, two studies in the adjuvant setting - MonarchE (2 years of abemaciclib) and NATALEE (3 years of ribociclib) - report positive invasive disease-free survival. Here, we re-evaluate these seminal trials. First, an excess drop-out or loss-to-follow up occurred early in the control arms of both studies. Since both trials are open-label, there is concern that the patients who drop-out do not do so at random but based on socioeconomic factors and alternative options. Is it possible that the results merely appear favorable due to loss to follow up? Based on re-constructed Kaplan-Meier curves, we concluded the results of these studies remain fragile, being prone to informative censoring. Secondly, adverse events were notably higher in both trials, and some of them, like COVID-19 related deaths in NATALEE, raise serious concerns. Third, the potential costs associated with CDK4/6 inhibition given as adjuvant therapy are unprecedented. The NATALEE strategy, in particular, could affect up to 35 % of patients with newly diagnosed breast cancer, which is the cancer with the highest incidence worldwide. Without confirmatory data based on a placebo-controlled trial, or better identification of patients that would benefit from the addition of CDK4/6 inhibitors in the adjuvant setting, we argue against their routine use as adjuvant therapy in ER+ /HER2- early breast cancer.
引用
- Haslam A, Ranganathan S, Prasad V, et al. CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms. Eur J Cancer. 2024. PMID: 38959677. doi:10.1016/j.ejca.2024.114192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。